Effect and mechanism of Kappa opioid agonist on intraoperative lung protection in patients with medium and high risk of pulmonary complications

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300073969

Enrollment

Unknown

Registered

2023-07-26

Start date

2023-01-17

Completion date

Unknown

Last updated

2023-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary complications

Interventions

Experimental group:butorphanol

Control group:Saline

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age= 18 years old; (2) ASA Grading I-III; (3) Patients with intermediate and high risk of pulmonary complications according to ARISCAT score (=26 points); (4) The estimated postoperative hospital stay is more than 24 hours; (5) Upper abdominal surgery (radical gastric resection) or thoracic surgery (pneumonectomy)

Exclusion criteria

Exclusion criteria: (1) Pregnancy or breastfeeding; (2) Severe liver and kidney diseases; (3) presence of obstructive sleep apnea; (4) The use of butorphanol tartrate is contraindicated; (5) history of opioid abuse; (6) Psychiatric disease or impaired consciousness before surgery; (7) Use of ventilator before surgery; (8) The duration of the operation is less than 0.5 h; (9) Cognitive dysfunction before surgery; (10) Refusal to sign informed consent.

Design outcomes

Primary

Measure	Time frame
Incidence of postoperative pulmonary complications;	—

Countries

China

Contacts

Public ContactZeng Si

Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital

63637936@qq.com+86 177 0813 0275

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026